Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 11/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717646 | 0.87 | NAMPT (0.47) | NAMPTNPSR1 | |
| SCHEMBL4789267 | 0.85 | NAMPT (0.46) | NAMPT | |
| SCHEMBL14221973 | 0.84 | NAMPT (0.46) | NAMPTMEN1KMT2A | |
| SCHEMBL14222058 | 0.82 | NAMPT (0.46) | NAMPT | |
| SCHEMBL4760969 | 0.82 | NAMPT (0.48) | NAMPT | |
| SCHEMBL4715869 | 0.81 | NAMPT (0.45) | NAMPTCACNA1GCACNA1HCACNA1I | |
| SCHEMBL4760017 | 0.80 | ITGB3 (0.54) | NAMPT | |
| SCHEMBL4762284 | 0.79 | ITGB3 (0.53) | NAMPT | |
| SCHEMBL4717998 | 0.79 | NAMPT (0.43) | NAMPT | |
| SCHEMBL4714544 | 0.79 | NAMPT (0.47) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | claimed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |